124 related articles for article (PubMed ID: 2283892)
1. Simplified long term large scale production of highly active human LAK cells for therapy.
Wersäll P; Masucci G; Pihlstedt P; Wigzell H; Mellstedt H
Med Oncol Tumor Pharmacother; 1990; 7(4):257-63. PubMed ID: 2283892
[TBL] [Abstract][Full Text] [Related]
2. Generation of human LAK cells in tissue culture bags using recombinant IL-2 and serum free medium. Effects of pretreatment with phenylalanine-methylester.
Wersäll P; Masucci G; Pihlstedt P; Cotgreave I; Tribukait B; Ullberg M; Wigzell H; Mellstedt H
Acta Oncol; 1990; 29(4):431-7. PubMed ID: 2390269
[TBL] [Abstract][Full Text] [Related]
3. Human lymphokine-activated killer (LAK) cells. I. Depletion of monocytes from peripheral blood mononuclear cells by L-phenylalanine methyl ester: an optimization of LAK cell generation at high cell density.
Leung KH
Cancer Immunol Immunother; 1989; 30(4):247-53. PubMed ID: 2598193
[TBL] [Abstract][Full Text] [Related]
4. Human lymphokine-activated killer (LAK) cells: III. Effect of L-phenylalanine methyl ester on LAK cell activation from human peripheral blood mononuclear cells: possible protease involvement of monocytes, natural killer cells and LAK cells.
Leung KH
Cancer Immunol Immunother; 1991; 34(1):31-6. PubMed ID: 1760808
[TBL] [Abstract][Full Text] [Related]
5. Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.
Roussel E; Gerrard JM; Greenberg AH
Clin Exp Immunol; 1990 Nov; 82(2):416-21. PubMed ID: 1700746
[TBL] [Abstract][Full Text] [Related]
6. A high density cell culture system for generation of human lymphokine-activated killer (LAK) cells for clinical use in adoptive immunotherapy.
Shimizu K; Park K; Yamada M; Tarura K; Matsui Y; Hayakawa T
J Clin Lab Immunol; 1990 May; 32(1):41-7. PubMed ID: 1967036
[TBL] [Abstract][Full Text] [Related]
7. The influence of cryopreservation on activity and surface markers of lymphokine-activated killer cells.
Letellier C; Rameliarison L; Fizet D; Ferrer AM; Vezon G
Vox Sang; 1991; 61(2):90-5. PubMed ID: 1763504
[TBL] [Abstract][Full Text] [Related]
8. Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii.
Subauste CS; Dawson L; Remington JS
J Exp Med; 1992 Dec; 176(6):1511-9. PubMed ID: 1460415
[TBL] [Abstract][Full Text] [Related]
9. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
10. Effects of OK-432 on the proliferation and cytotoxicity of lymphokine-activated killer (LAK) cells.
Yamamoto K; Tanaka R; Yoshida S; Ono K; Mori H; Taniguchi Y; Oda T; Watanabe T
J Immunother; 1999 Jan; 22(1):33-40. PubMed ID: 9924697
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of interleukin-6-enhanced lymphokine-activated killer cell function.
Iho S; Shau HY; Golub SH
Cell Immunol; 1991 Jun; 135(1):66-77. PubMed ID: 2018984
[TBL] [Abstract][Full Text] [Related]
13. IL-6 enhances the cytotoxic activity of thymocyte-derived CD56+ cells.
Iho S; Shau H; Golub SH
Cell Immunol; 1992 Oct; 144(1):1-10. PubMed ID: 1382861
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of superior anti-tumor cytotoxic response of interleukin 15-induced lymphokine-activated killer cells.
Ozdemir O; Ravindranath Y; Savaşan S
J Immunother; 2005; 28(1):44-52. PubMed ID: 15614044
[TBL] [Abstract][Full Text] [Related]
15. Isolation of human NK cells and generation of LAK activity.
Whiteside TL
Curr Protoc Immunol; 2001 May; Chapter 7():Unit 7.7. PubMed ID: 18432847
[TBL] [Abstract][Full Text] [Related]
16. High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells.
Koberda J; Bergmann L; Mitrou PS; Hoelzer D
J Cancer Res Clin Oncol; 1991; 117(5):425-30. PubMed ID: 1909699
[TBL] [Abstract][Full Text] [Related]
17. Lymphokine-activated killer cell generation and recovery. Comparison of an automated cell processing device and a manual procedure.
Ryan T; Atkins MB; Mier JW; Berkman EM
Transfusion; 1989; 29(6):491-5. PubMed ID: 2787549
[TBL] [Abstract][Full Text] [Related]
18. The role of lymphotoxin in the IL-2-driven differentiation of human lymphokine-activated T-killer (T-LAK) cells in vitro.
Abe Y; Van Eden M; Gatanaga M; Wang FI; Brightbill HD; Granger GA; Gatanaga T
Lymphokine Cytokine Res; 1993 Oct; 12(5):279-83. PubMed ID: 8260536
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of cytolytic activity and cell surface phenotypes of lymphokine activated killer cells stimulated with R-IL 2 and an anti-CD 3 antibody].
Kikuchi T; Sakai H; Nakamura N; Watanabe M; Ohno T
No To Shinkei; 1990 Jun; 42(6):575-80. PubMed ID: 2119634
[TBL] [Abstract][Full Text] [Related]
20. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
